Correction: Zilucoplan: First Approval
(Source: Drugs)
Source: Drugs - March 19, 2024 Category: Drugs & Pharmacology Source Type: research
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1
(Source: Drugs)
Source: Drugs - March 15, 2024 Category: Drugs & Pharmacology Source Type: research
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?
AbstractTamoxifen, a cornerstone in the adjuvant treatment of estrogen receptor-positive breast cancer, significantly reduces breast cancer recurrence and breast cancer mortality; however, its standard adjuvant dose of 20 mg daily presents challenges due to a broad spectrum of adverse effects, contributing to high discontinuation rates. Dose reductions of tamoxifen might be an option to reduce treatment-related toxicity, but large randomized controlled trials investigating the tolerability and, more importantly, efficacy of low-dose tamoxifen in the adjuvant setting are lacking. We conducted an extensive literature search ...
Source: Drugs - March 14, 2024 Category: Drugs & Pharmacology Source Type: research
Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability
AbstractCurrently, there are four monoclonal antibodies (mAbs) that target the cluster of differentiation (CD) 20 receptor available to treat multiple sclerosis (MS): rituximab, ocrelizumab, ofatumumab, and ublituximab. B-cell depletion therapy has changed the therapeutic landscape of MS through robust efficacy on clinical manifestations and MRI lesion activity, and the currently available anti-CD20 mAb therapies for use in MS are a cornerstone of highly effective disease-modifying treatment. Ocrelizumab is currently the only therapy with regulatory approval for primary progressive MS. There are currently few data regardin...
Source: Drugs - March 14, 2024 Category: Drugs & Pharmacology Source Type: research
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?
AbstractTamoxifen, a cornerstone in the adjuvant treatment of estrogen receptor-positive breast cancer, significantly reduces breast cancer recurrence and breast cancer mortality; however, its standard adjuvant dose of 20 mg daily presents challenges due to a broad spectrum of adverse effects, contributing to high discontinuation rates. Dose reductions of tamoxifen might be an option to reduce treatment-related toxicity, but large randomized controlled trials investigating the tolerability and, more importantly, efficacy of low-dose tamoxifen in the adjuvant setting are lacking. We conducted an extensive literature search ...
Source: Drugs - March 14, 2024 Category: Drugs & Pharmacology Source Type: research
Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability
AbstractCurrently, there are four monoclonal antibodies (mAbs) that target the cluster of differentiation (CD) 20 receptor available to treat multiple sclerosis (MS): rituximab, ocrelizumab, ofatumumab, and ublituximab. B-cell depletion therapy has changed the therapeutic landscape of MS through robust efficacy on clinical manifestations and MRI lesion activity, and the currently available anti-CD20 mAb therapies for use in MS are a cornerstone of highly effective disease-modifying treatment. Ocrelizumab is currently the only therapy with regulatory approval for primary progressive MS. There are currently few data regardin...
Source: Drugs - March 14, 2024 Category: Drugs & Pharmacology Source Type: research
Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials
ConclusionsThe results of the comprehensive analysis suggested hypoglycemic drug therapy as an effective intervention for NAFLD, with or without diabetes mellitus. A prioritized selection of TZDs, vitamin E plus pioglitazone, GLP-1 receptor agonists and FGF-21 analogue may be considered for NASH resolution. Obeticholic acid, lanifibranor and silymarin could be considered for the improvement of liver fibrosis. Each medication was relatively safe compared with placebo. (Source: Drugs)
Source: Drugs - March 13, 2024 Category: Drugs & Pharmacology Source Type: research
Fidanacogene Elaparvovec: First Approval
This article summarizes the milestones in the development of fidanacogene elaparvovec leading to this first approval for moderately severe to severe (factor IX activity ≤ 2%) haemophilia B who are negative for neutralizing antibodies to AAVRh74var. (Source: Drugs)
Source: Drugs - March 12, 2024 Category: Drugs & Pharmacology Source Type: research
Opioids for Acute Musculoskeletal Pain: A Systematic Review with Meta-Analysis
DiscussionIntravenous morphine likely offers benefits, but oral opioids may not provide clinically meaningful benefits.PROSPERO registrationCRD42021249346. (Source: Drugs)
Source: Drugs - March 7, 2024 Category: Drugs & Pharmacology Source Type: research
Adult-Onset Still ’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options
AbstractAdult-onset Still ’s disease (AOSD) is a multisystemic complex disorder clinically characterised by episodes of spiking fever, evanescent rash, polyarthritis or diffuse arthralgias; multiorgan involvement may develop according to the hyper-inflammatory extent. The pathogenesis of AOSD is not completely recognised. The central role of macrophage activation, which results in T helper 1 (Th1) cell cytokine activation, is well established. Pro-inflammatory cytokines such as interleukin (IL)-1, IL-6 and IL-18 play a fundamental role in disease onset and progression. The disease may develop in both children and adu lts...
Source: Drugs - March 5, 2024 Category: Drugs & Pharmacology Source Type: research
